Graft Enhancement, Immunologic
"Graft Enhancement, Immunologic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The induction of prolonged survival and growth of allografts of either tumors or normal tissues which would ordinarily be rejected. It may be induced passively by introducing graft-specific antibodies from previously immunized donors, which bind to the graft's surface antigens, masking them from recognition by T-cells; or actively by prior immunization of the recipient with graft antigens which evoke specific antibodies and form antigen-antibody complexes which bind to the antigen receptor sites of the T-cells and block their cytotoxic activity.
Graft Enhancement, Immunologic
- Graft Enhancement, Immunologic
- Immunologic Graft Enhancement
- Graft Enhancement, Immunological
- Enhancement, Immunological Graft
- Enhancements, Immunological Graft
- Graft Enhancements, Immunological
- Immunological Graft Enhancement
- Immunological Graft Enhancements
- Enhancement, Immunologic Graft
- Enhancements, Immunologic Graft
- Graft Enhancements, Immunologic
- Immunologic Graft Enhancements
- Immunologic Enhancement of Grafts
- Graft Enhancement
- Enhancement, Graft
- Enhancements, Graft
- Graft Enhancements
Below are MeSH descriptors whose meaning is more general than "Graft Enhancement, Immunologic".
Below are MeSH descriptors whose meaning is more specific than "Graft Enhancement, Immunologic".
This graph shows the total number of publications written about "Graft Enhancement, Immunologic" by people in Harvard Catalyst Profiles by year, and whether "Graft Enhancement, Immunologic" was a major or minor topic of these publication.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
Below are the most recent publications written about "Graft Enhancement, Immunologic" by people in Profiles.
T-cell co-stimulatory blockade in transplantation: two steps forward one step back! Expert Opin Biol Ther. 2013 Nov; 13(11):1557-68.
Primary vascularization of allografts governs their immunogenicity and susceptibility to tolerogenesis. J Immunol. 2013 Aug 15; 191(4):1948-56.
Pillars article: long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature. 1996. 381: 434-438. 1996. J Immunol. 2011 Mar 01; 186(5):2693-7.
Activation, immune polarization, and graft-versus-leukemia activity of donor T cells are regulated by specific subsets of donor bone marrow antigen-presenting cells in allogeneic hemopoietic stem cell transplantation. J Immunol. 2009 Dec 15; 183(12):7799-809.
Proinflammatory cytokine effects on mesenchymal stem cell therapy for the ischemic heart. Ann Thorac Surg. 2009 Sep; 88(3):1036-43.
The function of donor versus recipient programmed death-ligand 1 in corneal allograft survival. J Immunol. 2007 Sep 15; 179(6):3672-9.
Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2006 Dec; 12(12):1239-49.
Immunosuppressive and trafficking properties of donor splenic and bone marrow dendritic cells. Transplantation. 2006 Feb 15; 81(3):455-62.
TLR agonists abrogate costimulation blockade-induced prolongation of skin allografts. J Immunol. 2006 Feb 01; 176(3):1561-70.
Induction of donor-specific tolerance in sublethally irradiated recipients by gene therapy. Mol Ther. 2005 Aug; 12(2):353-9.